Neuronetics to Report First Quarter 2023 Financial and Operating Results and Host Conference Call

Rhea-AI Summary

MALVERN, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Neuronetics, a medical technology company focused on neurohealth, announced it will release its first quarter 2023 financial and operating results before the market opens on May 9, 2023. A conference call is scheduled for the same day at 8:30 a.m. Eastern Time to discuss these results.

The call will be accessible via a live webcast and participants can register for phone access in advance. Neuronetics emphasizes the importance of mental health, offering its NeuroStar Advanced Therapy, a non-invasive treatment for major depressive disorder (MDD) and other conditions. NeuroStar has delivered over 5.3 million treatments and is backed by extensive clinical data, making it a leader in transcranial magnetic stimulation (TMS) therapies.

MALVERN, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release first quarter 2023 financial and operating results prior to market open on Tuesday, May 9th, 2023. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/dkh33hi3. To listen to the conference call on your telephone, participants may register for the call here. While it is not required, it is recommended you join 10 minutes prior to the event start.

About Neuronetics

Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 5.3 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, www.neurostar.com.

Investor Contact:
Mike Vallie or Mark Klausner
ICR Westwicke
443-213-0499
ir@neuronetics.com

Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com

FAQ

When will Neuronetics release its Q1 2023 financial results?

Neuronetics will release its first quarter 2023 financial results on May 9, 2023.

What time is the Neuronetics conference call scheduled for May 9, 2023?

The Neuronetics conference call is scheduled for 8:30 a.m. Eastern Time on May 9, 2023.

How can I listen to the Neuronetics conference call?

The conference call can be listened to via a live webcast or by registering for phone access.

What is NeuroStar and its significance to Neuronetics?

NeuroStar is a non-invasive treatment for major depressive disorder, delivering over 5.3 million treatments and backed by extensive clinical data.

Is NeuroStar FDA-cleared?

Yes, NeuroStar is FDA-cleared for adults with major depressive disorder and other related conditions.